Early season co-circulation of influenza A(H3N2) and B(Yamagata): interim estimates of 2017/18 vaccine effectiveness, Canada, January 2018

被引：69

作者：

Skowronski, Danuta M. ^{[1
,2
]}

Chambers, Catharine ^{[1
]}

De Serres, Gaston ^{[3
,4
,5
]}

Dickinson, James A. ^{[6
]}

Winter, Anne-Luise ^{[7
]}

Hickman, Rebecca ^{[1
]}

Chan, Tracy ^{[1
]}

Jassem, Agatha N. ^{[1
,2
]}

Drews, Steven J. ^{[8
,9
]}

Charest, Hugues ^{[3
]}

Gubbay, Jonathan B. ^{[7
,10
]}

Bastien, Nathalie ^{[11
]}

Li, Yan ^{[11
]}

Krajden, Mel ^{[1
,2
]}

机构：

[1] British Columbia Ctr Dis Control, Vancouver, BC, Canada

[2] Univ British Columbia, Vancouver, BC, Canada

[3] Inst Natl Sante Publ Quebec, Quebec City, PQ, Canada

[4] Laval Univ, Quebec City, PQ, Canada

[5] Ctr Hosp Univ Quebec, Quebec City, PQ, Canada

[6] Univ Calgary, Calgary, AB, Canada

[7] Publ Hlth Ontario, Toronto, ON, Canada

[8] Alberta Prov Lab, Edmonton, AB, Canada

[9] Univ Alberta, Edmonton, AB, Canada

[10] Univ Toronto, Toronto, ON, Canada

[11] Publ Hlth Agcy Canada, Natl Microbiol Lab, Winnipeg, MB, Canada

来源：

EUROSURVEILLANCE | 2018年 / 23卷 / 05期

关键词：

SURVEILLANCE NETWORK; UNITED-STATES;

D O I：

10.2807/1560-7917.ES.2018.23.5.18-00035

中图分类号：

R51 [传染病];

学科分类号：

100401 ;

摘要：

Using a test-negative design, we assessed interim vaccine effectiveness (VE) for the 2017/18 epidemic of co-circulating influenza A(H3N2) and B(Yamagata) viruses. Adjusted VE for influenza A(H3N2), driven by a predominant subgroup of clade 3C.2a viruses with T131K + R142K + R261Q substitutions, was low at 17% (95% confidence interval (CI): -14 to 40). Adjusted VE for influenza B was higher at 55% (95% CI: 38 to 68) despite prominent use of trivalent vaccine containing lineage-mismatched influenza B(Victoria) antigen, suggesting cross-lineage protection.

引用

页码：2 / 8

页数：7

共 22 条

[1]

Allen UD, GUIDANCE USE ANTIVIR

[2]

[Anonymous], WHO REC COMP INFL VI

[3] Variable influenza vaccine effectiveness by subtype: a systematic review and meta-analysis of test-negative design studies [J].

Belongia, Edward A. ;

Simpson, Melissa D. ;

King, Jennifer P. ;

Sundaram, Maria E. ;

Kelley, Nicholas S. ;

Osterholm, Michael T. ;

McLean, Huong Q. .

LANCET INFECTIOUS DISEASES, 2016, 16 (08) :942-951

[4]

British Columbia Centre for Disease Control (BCCDC), CAN SENT PRACT SURV

[5]

Centers for Disease Control and Prevention (CDC), 2018, FLUVIEW WEEKL US INF

[6] Interim estimates of 2015/16 vaccine effectiveness against influenza A(H1N1)pdm09, Canada, February 2016 [J].

Chambers, C. ;

Skowronski, D. M. ;

Sabaiduc, S. ;

Winter, A. L. ;

Dickinson, J. A. ;

De Serres, G. ;

Gubbay, J. B. ;

Drews, S. J. ;

Martineau, C. ;

Eshaghi, A. ;

Krajden, M. ;

Bastien, N. ;

Li, Y. .

EUROSURVEILLANCE, 2016, 21 (11) :27-34

[7] Update: Influenza Activity - United States, October 1-November 25, 2017 [J].

Dugan, Vivien G. ;

Blanton, Lenee ;

Abd Elal, Anwar Isa ;

Alabi, Noreen ;

Barnes, John ;

Brammer, Lynnette ;

Burns, Erin ;

Cummings, Charisse N. ;

Davis, Todd ;

Flannery, Brendan ;

Fry, Alicia M. ;

Garg, Shikha ;

Garten, Rebecca ;

Gubareva, Larisa ;

Jang, Yunho ;

Kniss, Krista ;

Kramer, Natalie ;

Lindstrom, Stephen ;

Mustaquim, Desiree ;

O'Halloran, Alissa ;

Olsen, Sonja J. ;

Sessions, Wendy ;

Taylor, Calli ;

Trock, Susan ;

Xu, Xiyan ;

Wentworth, David E. ;

Katz, Jacqueline ;

Jernigan, Daniel .

MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT, 2017, 66 (48) :1318-1326

[8]

ECDC, 2017, INFL VIR CHAR SUMM E

[9]

European Centre for Disease Prevention and Control (ECDC), 2018, FLU NEW EUR JOINT EC

[10]

Ferdinands J., 2017, ADVISORY COMMITTEE I

← 1 2 3 →